$RAPH
Raphael Pharmaceutical Inc.
CIK:0001415397|SEC Filings
Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Income Statement [Abstract] | ||||
| Research and development expenses | $ 40 | $ 141 | $ 77 | $ 213 |
| General and administrative expenses | 159 | 174 | 345 | 527 |
| Operating loss | 199 | 315 | 422 | 740 |
| Total financial expense | 24 | 7 | 30 | 11 |
| Net loss | $ 223 | $ 322 | $ 452 | $ 751 |
| Basic net loss per share (in Dollars per share) | $ 0.01 | $ 0.02 | $ 0.02 | $ 0.04 |
| Diluted net loss per share (in Dollars per share) | $ 0.01 | $ 0.02 | $ 0.02 | $ 0.04 |
| Weighted average number of shares of common stock used in computing basic net loss per share (in Shares) | 20,176,418 | 19,626,418 | 20,176,418 | 19,370,534 |
| Weighted average number of shares of common stock used in computing diluted net loss per share (in Shares) | 20,176,418 | 19,626,418 | 20,176,418 | 19,370,534 |
Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands |
6 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Cash flows from operating activities | ||||
| Net loss | $ (452) | $ (751) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Share-based payment in exchange for services | 205 | |||
| Interest accrued on short term loan | 9 | |||
| Depreciation | [1] | 1 | ||
| Changes in: | ||||
| Other current assets | 1 | (2) | ||
| Related parties | 364 | 336 | ||
| Account payables and accrued expenses | 33 | (27) | ||
| Net cash used in operating activities | (44) | (239) | ||
| Issuance of common stock and warrants | 240 | |||
| Net cash provided by financing activities | 240 | |||
| Change in cash and cash equivalents | (44) | 1 | ||
| Cash and cash equivalents at the beginning of the period | 45 | 19 | ||
| Cash and cash equivalents at the end of the period | $ 1 | $ 20 | ||
| ||||
Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands |
Jun. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1 | $ 45 |
| Other current assets | 5 | 6 |
| Total current assets | 6 | 51 |
| Fixed assets, net | 1 | 2 |
| Total assets | 7 | 53 |
| Current liabilities: | ||
| Other account payables and accrued expenses | 539 | 506 |
| Total current liabilities | 1,892 | 1,486 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.01 par value: Authorized: 50,000,000 shares at June 30, 2026, and 21,020,560 shares at December 31, 2025; Issued and outstanding: 20,176,418 at June 30, 2026 and at December 31, 2025. | 202 | 202 |
| Additional paid-in capital | 8,533 | 8,533 |
| Accumulated deficit | (10,620) | (10,168) |
| Total stockholders’ equity (deficit) | (1,885) | (1,433) |
| Total liabilities and stockholders’ equity (deficit) | 7 | 53 |
| Related party | ||
| Current liabilities: | ||
| Short-term credit from a related party | 43 | 34 |
| Payable to related party | $ 1,310 | $ 946 |